What our research found
Metafit Pharma Solutions, Inc. operates the TrimRx technology and administrative platform. Current legal and privacy materials separate that role from medical care. Independent affiliated physician groups and U.S.-licensed clinicians determine eligibility and prescribe, while participating pharmacies dispense approved prescriptions.
The current site does not publish the name of the patient-specific medical group, clinician, or dispensing pharmacy before intake. It refers instead to third-party clinician networks and state-licensed sterile compounding or participating pharmacies. The prescription notice and final label should identify the actual prescriber, pharmacy, ingredients, concentration, quantity, storage, and beyond-use date.
The main intake is described as a free two-minute assessment. A licensed U.S. provider reviews the submitted history, and the current plan selector says review occurs within 24 hours. A short telehealth call may be arranged when additional consultation or state law requires it. Completing the questionnaire does not guarantee approval or a prescription.
TrimRx's primary prescription program uses compounded medication. Its safety and legal pages correctly state that compounded drugs are not FDA approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Pharmacy registration or licensure is a facility status, not approval of the finished patient-specific product.
The compact comparison section contains compounded semaglutide and compounded tirzepatide injections. The public selector says each month represents a four-week vial supply dosed weekly, dose increases are included, and all dose levels share the displayed plan rate. Exact concentration, additives, injection volume, and titration remain prescription-specific.
The semaglutide selector shows non-discounted plan rates of $299 for one month, $249 per month for three months, $211 per month for six months, and $184 per month for twelve months. Those correspond to commitments of $299, $747, $1,266, and $2,208. The four effective monthly rates average $235.75, displayed as Avg. $236/mo.
The tirzepatide selector shows non-discounted plan rates of $399 for one month, $356 per month for three months, $319 per month for six months, and $293 per month for twelve months. Those correspond to commitments of $399, $1,068, $1,914, and $3,516. The four effective monthly rates average $341.75, displayed as Avg. $342/mo.
A current countdown selector advertises a 28% lifetime discount. It lowers semaglutide rates to $215, $179, $152, and $133 per month, and tirzepatide rates to $287, $256, $230, and $211 per month across the same terms. The temporary offer is excluded from the cards, and no promotion appears beneath the CTA because no affiliate tracking link or network-compatible benefit has been issued.
Pricing conflicts are material. The homepage advertises GLP-1 from $179 and GLP-1 plus GIP from $259. Product pages show compounded GLP-1 at $199 after a $299 strike-through and compounded tirzepatide at $349 after $449. The current legal terms instead list $199 initial and $299 follow-up for GLP-1, plus $349 initial and $399 follow-up for GLP-1 plus GIP.
Because current official pages disagree, both average cards remain outside the broader price benchmark. The card math is reproducible for the selector schedule, but it does not establish which schedule a new patient will actually receive. Confirm the first charge, full commitment, financing, shipment cadence, renewal schedule, and post-discount rate at checkout.
The current selector says monthly plans ship every month, while three-month plans ship a 12-week supply and six- or twelve-month plans ship every three months. All plans advertise free expedited shipping, an injection kit, unlimited medical support, and seven-day online support. Third-party financing may be available, but financing terms belong to the financing provider.
Current legal terms describe prepaid multi-month subscriptions and permit cancellation to prevent future unfilled orders. A refund for the unused prepaid portion requires a separate request within 28 days of the payment date. After that window, cancellation may stop future fulfillment but does not make the unused prepaid portion refundable except where law or another policy provision applies.
The current order can be canceled before the prescription is transmitted to the pharmacy. Once transmission occurs, that order continues through fulfillment, although cancellation can still apply to future unfilled orders. Medical disqualification and a TrimRx billing error qualify for a full refund under the current terms.
The shipping policy says most patients receive medication approximately four to seven business days after prescription approval. Delivery after the pharmacy dispatches is estimated at three to five business days. Tracking is provided, and a patient may request a refund if medication has not shipped within 14 days of the order.
Lost or damaged shipments are reviewed with the carrier and pharmacy, and an appropriate case may receive a replacement. A delivery estimate is not a guarantee; pharmacy volume, carrier delays, weather, holidays, state rules, and address accuracy can change timing.
Current first-party articles do not present one consistent laboratory policy. One says TrimRx typically does not require pretreatment labs for a healthy patient, another says labs may be ordered case by case, and others describe bloodwork as mandatory. The operative terms and plan-inclusion list do not promise a routine included panel. Treat laboratory timing and cost as clinician-dependent until the order states otherwise.
The site advertises oral GLP-1 and oral tirzepatide routes, but the public pages contain approval and ingredient language that requires careful reconciliation with the actual prescription. These routes stay editorial-only rather than becoming extra cards. Confirm active ingredient, salt or base, dosage form, strength, quantity, and regulatory status with the prescriber and pharmacy.
TrimRx also advertises access to Ozempic, Wegovy, Mounjaro, and Zepbound. Current safety language says the patient may receive a prescription to fill at a pharmacy and remains responsible for branded medication cost, while current terms and product pages publish different bundled or one-time figures. No branded card is shown until fulfillment and pricing are consistent.
The current terms advertise service in all 50 U.S. states and no international shipping. Actual eligibility remains treatment-specific and depends on clinician licensure, telehealth law, pharmacy capacity, inventory, and the patient's current location.
TrimRx publishes phone support at 888-896-1612 seven days a week from 6 a.m. to 6 p.m. Pacific. Email is hello@trimrx.com, and the site advertises portal support around the clock plus unlimited medical support. Those access channels do not replace emergency or local in-person care.
The site says no insurance is needed for the compounded program. A self-pay customer should verify HSA or FSA treatment with the benefit administrator before relying on reimbursement and should retain the itemized receipt and prescription.
One Katalys application is pending for Trim Rx under offer 1515. The recorded payout is $300 and the discovery EPC is $22.69. No tracking URL has been issued. Payout and EPC affected research order only and did not change the score, findings, or CTA.
- Two canonical ingredient cards replace oral-route, branded, and supplement marketing variants.
- Selector standard rates average $236 per month for semaglutide and $342 per month for tirzepatide; the timed 28% offer stays in notes.
- Free shipping, supplies, clinician access, tracking, seven-day support, and a four-to-seven-business-day delivery estimate are public.
- Pricing, branded fulfillment, and laboratory requirements conflict across current official pages, so checkout and written confirmation matter.
